-
Je něco špatně v tomto záznamu ?
COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population
N. Mallah, J. Pardo-Seco, I. Rivero-Calle, O. Zhu-Huang, M. Fernández Prada, C. Reynen-de Kat, O. Benes, L. Mosina, S. Sankar-Datta, O. Aleksinskaya, D. Díaz, V. Allahverdiyeva, Y. Grechukha, T. Jobava, M. Savchyna, P. Kortusova, I. Novac, F....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
001
World Health Organization - International
NLK
Directory of Open Access Journals
od 2022
Free Medical Journals
od 2012 do Před 1 rokem
PubMed Central
od 2012 do Před 1 rokem
Europe PubMed Central
od 2012 do Před 1 rokem
Taylor & Francis Open Access
od 2022-04-01
Medline Complete (EBSCOhost)
od 2022-01-01
- MeSH
- COVID-19 * prevence a kontrola epidemiologie MeSH
- dospělí MeSH
- lidé MeSH
- odkládání očkování statistika a číselné údaje MeSH
- SARS-CoV-2 imunologie MeSH
- sociální média * MeSH
- Světová zdravotnická organizace MeSH
- vakcinace * statistika a číselné údaje psychologie MeSH
- vakcíny proti COVID-19 * aplikace a dávkování MeSH
- zdravotní výchova metody MeSH
- zdravotnický personál statistika a číselné údaje MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
COVID-19 vaccine uptake varied across countries, in part due to vaccine hesitancy fueled by a lack of trustworthy information. To help health workers provide evidence-based answers to common questions about COVID-19 vaccines and vaccination, and thereby, assist individuals ́ decisions on vaccine acceptance, COVID-19 InfoVaccines, a joint WHO-EU project, was launched in February 2021 to support COVID-19 vaccine rollout in 6 Eastern European countries. COVID-19 InfoVaccines was made available in seven languages and shared on social media networks. A total of 262,592 users accessed COVID-19 InfoVaccines.com between February 11, 2021, and January 31st, 2023. The users were most interested in: general questions; vaccine efficacy and duration of protection; vaccine safety; vaccine co-administration, and dose-interval and interchangeability; though the interest in a specific theme varied in function of the epidemiological situation. A total of 118,510 (45.1%) and 46,644 (17.7%) users scrolled up to 35% and 75% of the COVID-19 InfoVaccines webpage, respectively. The average engagement rate was 71.61%. The users accessed COVID-19 InfoVaccines from 231 countries and territories, but the majority were in Ukraine (N = 38,404; 14.6%), Spain (N = 23,327; 8.9%), and Argentina (N = 21,167; 8.1%). Older Facebook users were more interested in COVID-19 information than younger individuals (X2 p-value < .0001). Two hundred twenty-eight videos were shared on YouTube. The average Click-Through-Rate on Facebook was 7.82%, and that on YouTube was 4.4%, with 60 videos having a Click-Through-Rate >5%, falling in the range of average YouTube video Click-Through-Rate (2% - 10%). As misinformation about vaccines and vaccination spreads easily and can negatively impact health-related decisions, initiatives like COVID-19 InfoVaccines are crucial to facilitate access to reliable information.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública Madrid Spain
Department of Preventive Medicine University of Santiago de Compostela Santiago de Compostela Spain
Digital Marketing Consultant and Project Manager World Health Organization Georgia
English Russian medical interpreter translator Russian Federation
Head of Design and Development Marketing agency Sisuco Solutions Madrid Spain
Servicio de Medicina Preventiva y Salud Pública Hospital Vital Álvarez Buylla Asturias Spain
WHO Collaborating Centre for Vaccine Safety Santiago de Compostela Spain
World Health Organization Country Office Bucharest Romania
World Health Organization Country Office Czechia
World Health Organization Country Office in Ukraine Kyiv Ukraine
World Health Organization Regional Office for Europe Copenhagen Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013274
- 003
- CZ-PrNML
- 005
- 20240905134200.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/21645515.2024.2350817 $2 doi
- 035 __
- $a (PubMed)38782400
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mallah, Narmeen $u Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain $u WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain $u Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain $u Department of Preventive Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
- 245 10
- $a COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population / $c N. Mallah, J. Pardo-Seco, I. Rivero-Calle, O. Zhu-Huang, M. Fernández Prada, C. Reynen-de Kat, O. Benes, L. Mosina, S. Sankar-Datta, O. Aleksinskaya, D. Díaz, V. Allahverdiyeva, Y. Grechukha, T. Jobava, M. Savchyna, P. Kortusova, I. Novac, F. Martinón-Torres
- 520 9_
- $a COVID-19 vaccine uptake varied across countries, in part due to vaccine hesitancy fueled by a lack of trustworthy information. To help health workers provide evidence-based answers to common questions about COVID-19 vaccines and vaccination, and thereby, assist individuals ́ decisions on vaccine acceptance, COVID-19 InfoVaccines, a joint WHO-EU project, was launched in February 2021 to support COVID-19 vaccine rollout in 6 Eastern European countries. COVID-19 InfoVaccines was made available in seven languages and shared on social media networks. A total of 262,592 users accessed COVID-19 InfoVaccines.com between February 11, 2021, and January 31st, 2023. The users were most interested in: general questions; vaccine efficacy and duration of protection; vaccine safety; vaccine co-administration, and dose-interval and interchangeability; though the interest in a specific theme varied in function of the epidemiological situation. A total of 118,510 (45.1%) and 46,644 (17.7%) users scrolled up to 35% and 75% of the COVID-19 InfoVaccines webpage, respectively. The average engagement rate was 71.61%. The users accessed COVID-19 InfoVaccines from 231 countries and territories, but the majority were in Ukraine (N = 38,404; 14.6%), Spain (N = 23,327; 8.9%), and Argentina (N = 21,167; 8.1%). Older Facebook users were more interested in COVID-19 information than younger individuals (X2 p-value < .0001). Two hundred twenty-eight videos were shared on YouTube. The average Click-Through-Rate on Facebook was 7.82%, and that on YouTube was 4.4%, with 60 videos having a Click-Through-Rate >5%, falling in the range of average YouTube video Click-Through-Rate (2% - 10%). As misinformation about vaccines and vaccination spreads easily and can negatively impact health-related decisions, initiatives like COVID-19 InfoVaccines are crucial to facilitate access to reliable information.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a vakcíny proti COVID-19 $x aplikace a dávkování $7 D000086663
- 650 12
- $a COVID-19 $x prevence a kontrola $x epidemiologie $7 D000086382
- 650 12
- $a sociální média $7 D061108
- 650 12
- $a vakcinace $x statistika a číselné údaje $x psychologie $7 D014611
- 650 _2
- $a odkládání očkování $x statistika a číselné údaje $7 D000088823
- 650 _2
- $a zdravotnický personál $x statistika a číselné údaje $7 D006282
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 650 _2
- $a zdravotní výchova $x metody $7 D006266
- 650 _2
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pardo-Seco, Jacobo $u Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain $u WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Rivero-Calle, Irene $u Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain $u WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain $u Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela and USC, Santiago de Compostela, Spain
- 700 1_
- $a Zhu-Huang, Ouhao $u Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain $u WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Fernández Prada, María $u Servicio de Medicina Preventiva y Salud Pública, Hospital Vital Álvarez Buylla, Asturias, Spain
- 700 1_
- $a Reynen-de Kat, Catharina $u World Health Organization Regional Office for Europe, Copenhagen, Denmark
- 700 1_
- $a Benes, Oleg $u World Health Organization Regional Office for Europe, Copenhagen, Denmark
- 700 1_
- $a Mosina, Liudmila $u World Health Organization Regional Office for Europe, Copenhagen, Denmark
- 700 1_
- $a Sankar-Datta, Siddhartha $u World Health Organization Regional Office for Europe, Copenhagen, Denmark
- 700 1_
- $a Aleksinskaya, Olga $u English-Russian medical interpreter/translator, Russian Federation
- 700 1_
- $a Díaz, David $u Head of Design and Development Marketing agency, Sisuco Solutions, Madrid, Spain
- 700 1_
- $a Allahverdiyeva, Vusala $u World Health Organization Country Office in Ukraine, Kyiv, Ukraine
- 700 1_
- $a Grechukha, Yevgenii $u World Health Organization Country Office in Ukraine, Kyiv, Ukraine
- 700 1_
- $a Jobava, Tamara $u Digital Marketing Consultant & Project Manager, World Health Organization, Georgia
- 700 1_
- $a Savchyna, Mariia $u World Health Organization Country Office in Ukraine, Kyiv, Ukraine
- 700 1_
- $a Kortusova, Pavla $u World Health Organization Country Office, Czechia
- 700 1_
- $a Novac, Ioana $u World Health Organization Country Office, Bucharest, Romania
- 700 1_
- $a Martinón-Torres, Federico $u Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain $u WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain $u Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela and USC, Santiago de Compostela, Spain $1 https://orcid.org/000000029023581X
- 773 0_
- $w MED00181409 $t Human vaccines & immunotherapeutics $x 2164-554X $g Roč. 20, č. 1 (2024), s. 2350817
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38782400 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134154 $b ABA008
- 999 __
- $a ok $b bmc $g 2143226 $s 1225140
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 20 $c 1 $d 2350817 $e 20240523 $i 2164-554X $m Human vaccines & immunotherapeutics $n Hum Vaccin Immunother $x MED00181409
- GRA __
- $a 001 $p World Health Organization $2 International
- LZP __
- $a Pubmed-20240725
